Transforming Coherus Adds To IO Pipeline Via Merger With Surface Oncology
Currently battling AbbVie over pricing plans for its Humira biosimilar, Coherus is also looking to become an immuno-oncology player, acquiring two more clinical assets in an all-stock deal.
You may also be interested in...
Plus deals involving Menarini/VenatoRx, Orion/Glykos, Roche/MOMA, Janssen/Elektrofi, Galapagos/BridGene along with 13 other transactions.
Plus deals involving ASLAN/Zenyaku Kogyo, AstraZeneca/Cholsegen, Astellas/Cullgen, AbCellera/Confo, Blue Water/WraSer, Solve/Cereius, Prime Medicine/Cimeio, Evox/Codiak, PharmaTher/Vitruvias and Adverum/Ray.
Coherus BioSciences’ plans earlier this month to launch its Humira biosimilar, Yusimry, at a massive discount have sparked both a legal battle and an arrangement with a “next generation” pharmacy benefit manager.